- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
Ingelheim, Germany, 15 May 2009
Boehringer Ingelheim will present new data on the company’s two lead oncology compounds, BIBW 2992* and BIBF 1120* at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company announced today. Two studies in the LUX-Lung clinical development programme for BIBW 2992* and a Phase II study of BIBF 1120* in ovarian cancer patients will be presented.
*BIBW 2992 and BIBF 1120 are investigational compounds. Their safety and efficacy have not yet been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
